During the current pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (Covid-19), has diversified considerably. As of September ...
Therefore, we administered a third 30-μg BNT162b2 dose 7.9 to 8.8 months after dose 2 to 11 participants 18 to 55 years of age and to 12 participants 65 to 85 years of age from U.S. sites in the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results